Abstract
“We see companies throughout the biopharma space struggling. The recent
spate of mega-mergers reflects the recognition of certain Big Pharmas that
their patent positions and pipelines are insufficient to maintain their
revenue stream. On the other end of the industry spectrum, biotechs continue
to falter as the international economy remains in recession. Even within the
generics industry, which has benefited in an environment of cost-containment,
companies are experiencing economy-related stumbles. Hope lies in new company
strategies that can yield focus and efficiency on a smaller scale, and in
innovative research - which will be buoyed by the U.S. financial stimulus
package.” - Catherine Cuddihee, Principal Director.
Introduction
No Bear Stearns, no Lehman Brothers, no Chrysler, no humiliating hat-in-hand
audiences with Congress. The biopharma industry has not seen one of its
leaders tumble in the way that the financial and automotive industries have.
Certainly, though, many smaller players are succumbing in the international
economic meltdown; major players are making moves that are critical to their
survival; and the possibility of a federal bailout of the biotech industry has
been raised. Clearly, the state of the economy is hastening change in the
industry, which will confront a narrowed playing field, greater
cost-consciousness, and opportunities to innovate in terms of technologies and
business models.
Get the Answers You Need to Shape Your Strategy
- The first quarter brought the return of the mega-merger. What do these
mammoth deals signal for the Big Pharma/Big Biotech participants? What do they
say about the industry in general?
- Healthcare reform debates continue in the United States. What is the
state of the coalition exploring change? What does the financial stimulus
package mean for healthcare?
- Small biotechs are suffering given the current economic condition. What
is the outlook for this sector? How has the investment environment been
affected? Where are the opportunities?
- Many companies are targeting biosimilar development, recognizing that
payers will embrace these alternatives. How is U.S. regulatory guidance
shaping up? What companies are pursuing biosimilar approvals? What is the
outlook for Teva, which has announced that it will pursue a biosimilar BLA?
Scope
- Events: guidance and approvals involving transgenic animals; biotech
industry financial and investment trends, challenges, opportunities, and
outlook; U.S. stimulus package funding in the healthcare arena.
- Dealmaking: deal volume, deal type, deal value, deal focus, most active
companies, therapeutic area focus, biologics focus.
- Generics: Actavis and Ratiopharm up for sale; layoffs announced at key
generics companies; the push for biosimilars.
- Strategy: return of the mega-merger; pending healthcare reform in the
United States; Big Pharma' s philanthropic ventures in developing countries.
- Expert commentary: “Biotech Investment Trends: The Quest for
Capital,” by Decision Resources senior analyst Barbara M. Bolten, M.S.,
M.B.A.
Mentioned in This Spectrum Report
- A*Star
- Abbott Laboratories
- Abbott Medical
- Optics
- Actavis
- AdultCells
- Advanced Medical
- Optics
- Affibody
- AgResearch
- Akesis
- Pharmaceuticals
- Alcon
- Altus
- Amgen
- Apex Biomedical
- Acquisition Partners
- Apitope
- Arana Therapeutics
- Aruna Biomedical
- Astellas Pharma
- AstraZeneca
- Aveo
- Pharmaceuticals
- Avigen
- Barr
- Baxter International
- Bayer AG
- Bayer Schering
- Pharma
- Beckman Coulter
- Bial-Portela & CA
- BioFocus
- Biogen Idec
- Biomarin
- Pharmaceuticals
- Biomatrix Scientific
- BioMosaics
- Biopartners
- Biovitrum
- Boehringer
- Ingelheim
- Bristol-Myers Squibb
- Capsant
- Cephalon
- Ception Therapeutics
- CHDI Institute
- Clontech
- CT Arzneimittel
- CV Therapeutics
- Cypress Biosciences
- Cytori
- Dako
- Dynogen
- Pharmaceuticals
- Eberhard-Karls-
- Universitaet
- Tuebingen
- Eisai
- Eli Lilly
- Embryome Sciences
- Endo
- Pharmaceuticals
- Entelos
- Epigenomics
- EvoStem
- Evotec
- Forest Laboratories
- Formatech
- Fujirebio
- Galapagos
- GE Healthcare
- Genavia Therapeutics
- GeneGo
- Genentech
- Genfit
- Gen-Probe
- Gilead Sciences
- GlaxoSmithKline
- Globalstem
- GTC
- BioTherapeutics
- Health Discovery
- Hexal
- Hospira
- Idenix
- Immunocellular
- Therapeutics
- Indevus
- Pharmaceuticals
- Insmed
- Isolagen
- Johnson & Johnson
- Karolinska
- Development
- La Jolla
- Pharmaceutical
- Lonza
- Lundbeck
- MannKind
- Marvel Life Sciences
- Mayo Foundation
- Merck & Co.
- Merck KGaA
- Merck Serono
- Micromet
- Momenta
- Pharmaceuticals
- Mylan
- NeoCells
- Neose Technologies
- Neurobiological
- Technologies
- NeuroSearch
- Nissan Chemical
- North American
- Scientific
- Novartis
- Novo Nordisk
- Novozymes
- Olympus
- Open Biosystems
- Origen Therapeutics
- OSI Pharmaceuticals
- Ovation
- Pharmaceuticals
- Peptimmune
- Pfizer
- PhenoPath
- Laboratories
- Plexxikon
- Pliva
- Portola
- Pharmaceuticals
- Provenance
- Biopharmaceuticals
- Quest Diagnostics
- Ratiopharm
- ReNeuron
- Reproductive
- Genetics Institute
- Roche
- Sandoz
- Sanofi-Aventis
- Santaris
- Pharmaceuticals
- Schering-Plough
- Sensigen
- Sequenom
- Shire
- Pharmaceuticals
- Sirius Genomics
- Stada
- Stemgent
- Symphogen
- Synageva BioPharma
- Sysmex
- Takeda
- Tapestry
- Pharmaceuticals
- Teijin Pharma
- Tepnel
- Tet Systems
- Teva Pharmaceutical
- Tocris Bioscience
- UCB
- UK Critical Care
- Genomics Group
- University of
- Glasgow
- Vanda
- Pharmaceuticals
- Vanderbilt University
- Vertex
- Pharmaceuticals
- ViroChem Pharma
- VistaGen
- Watson
- Pharmaceuticals
- Wyeth
- Xencor
- Zydus Cadila
- Zymogenetics
| 
View Cart
